Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

Fig. 2

Efficacy comparison of first-line therapy between PP ± B and PC + B. a. mPFS; b. mOS; c. ORR; d. PFSR1y. Abbreviations: PP ± B, pemetrexed-platinum with or without bevacizumab; PC + B, paclitaxel-carboplatin with bevacizumab; mPFS, median progression-free survival; mOS, median overall survival; ORR, objective response rates; PFSR1y, 1-year PFS rate

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us